Earlier this month, I had the opportunity to speak at a congressional event in Fort Lauderdale when Congresswoman Debbie Wasserman Schultz visited our manufacturing facility. The visit was a recognition of what pharmaceutical-grade stem cell manufacturing looks like in practice, and an opportunity to put on record something I feel strongly about.
What I said that day is worth repeating here.
Florida set an appropriately rigorous standard. The market has to catch up.
The Florida Standard
In 2025, Florida passed SB 1768, creating a defined commercial pathway for allogeneic, cGMP-manufactured stem cell therapies administered by licensed physicians. The law set specific requirements: living cells, pharmaceutical-grade manufacturing, physician oversight, documented informed consent. It drew hard lines around what is and is not permitted.
That was the right call. The regenerative medicine stem cell market has, for years, operated with minimal accountability. Products with no documented manufacturing standards, no sterility data, no viability testing, and no chain of custody have been sold alongside products that meet every standard the pharmaceutical industry would require. Patients could not tell the difference. In many cases, stem cell therapy providers could not either.
The Florida legislature looked at a chaotic and under-regulated market and decided patients deserved better.
What Pharmaceutical-Grade Manufacturing Actually Means
At TAVRA, every lot of mCell, our bone marrow-derived mesenchymal stromal cell (BM-MSC) therapy, is produced in an ISO 7 cleanroom under current Good Manufacturing Practice (cGMP) guidelines. Every vial ships with a lot-level Certificate of Analysis documenting viability, potency, purity, and sterility. The cell source is a validated, traceable master cell bank.
This is not unusual in pharmaceutical manufacturing. It is standard. What is unusual is how rarely it exists in the mesenchymal stem cell therapy market.
The overwhelming majority of allogeneic stem cell products currently offered to physicians in the United States are not manufactured to anything close to this standard. That gap is the central problem in this industry, and it is the problem SB 1768 was designed to address.
The Compliance Gap
Complying with SB 1768 is expensive. Pharmaceutical-grade manufacturing, third-party testing, regulatory documentation, and FDA-registered facility costs are real and significant.
Right now, that cost functions as a perverse incentive. Operators who cut corners face no meaningful consequences. Their products sit in the same market as ours, often at lower price points, with no visible signal to the physician or patient that anything is different. The compliance burden falls entirely on the companies doing it right, while non-compliant operators absorb none of it.
That has to change.
Compliance cannot be a penalty. It has to be the floor.
What This Means for Patients and Physicians
A physician ordering a biologic for a patient should be able to trust that what is in the vial matches what is on the label. That the cells are viable. That the product was handled correctly from the moment it was manufactured to the moment it arrived. That someone, somewhere, was accountable for every step of that process.
That is not a high bar. It is the minimum. And right now, much of the stem cell therapy market does not meet it.
Florida’s law creates the conditions for that to change. When compliant products are the standard and not the exception, physicians can evaluate therapies on clinical merit. Patients can make informed decisions. The conversation shifts from “is this product what it claims to be” to “is this therapy right for me.”
That is the market this industry should be building toward. TAVRA was built to meet this standard.